MaxCyte Hits High Notes in Challenging 2025 with Groundbreaking Launch of ExPERT DTx
MaxCyte, a leading biotechnology company, has made significant strides in a year marked by operational headwinds. Despite the challenges, the company demonstrated resilience and innovation, as highlighted during its recent Q4 2025 earnings call.
According to Maher Masoud, President and Chief Executive Officer of MaxCyte, the company navigated the complex landscape with finesse, signing new strategic platform licenses (SPLs) and supporting customers in advancing drugs through the clinic. A notable achievement was the acquisition of SeQure Dx and its successful integration into MaxCyte.
The company's financial results for Q4 2025 were within expectations, reporting $33 million of total revenue for the full year. This included $29.6 million of core revenue and $3.4 million of SPL-layer revenue, showcasing the growth potential of this segment. Furthermore, MaxCyte expanded its instrument install base to 857, a testament to the company's ability to adapt and evolve.
A standout development from the quarter was the launch of ExPERT DTx, a revolutionary modular 96-well electroporation platform. This groundbreaking product enables labs to transfect primary cells and cell lines across up to 96 samples in just three minutes, eliminating experimental variables and reducing waste. The DTx also boasts unique detachable 8-well strips that can be processed with distinct parameters, allowing researchers to test different cell and cargo combinations in parallel.
The ExPERT DTx software is equally impressive, offering users the ability to design experiments remotely and upload workflows when the system becomes available. This maximizes instrument pipeline and provides a practical advantage for labs conducting multiple back-to-back experiments.
What sets ExPERT DTx apart is its seamless compatibility with the rest of the ExPERT platform. Researchers can optimize processes on the DTx in discovery, transfer them directly to MaxCyte's larger-scale electroporation instruments (FCX or GTx), and scale up into cGMP compliant manufacturing without re-optimization. This represents a powerful value proposition that enables engagement with customers at the earliest stage of their workflow.
MaxCyte built ExPERT DTx around customer needs, and it is expected to contribute significantly to instrument and processing assembly revenue in 2026 and beyond. The product's launch also positions MaxCyte to grow its SPL customers, leveraging years of electroporation expertise and know-how. As the biotech industry continues to evolve, MaxCyte remains poised for success, driven by innovative products like ExPERT DTx.
